Each retrieved citation was reviewed by two independently working reviewers (A.R. and J.D.). Most articles were excluded on the basis of information provided by the title or abstract. Citations that appeared to be appropriate or those that could not be excluded unequivocally from the title and abstract were identified, and the corresponding full text reports were reviewed by the two reviewers. Any disagreement between them was resolved by reviewer consensus. From the included articles, the following data were extracted: patient demographics, diagnoses, type of surgery, reoperation risks, perioperative outcomes, adverse events, and predictive factors for outcome following LLIF surgery.
formed considering the following AHRQ required and additional domains. 5 ►Table 6 below provides an outline of the method used to determine the final SoE. Risk of bias is evaluated during the individual study evaluation described above. After individual article review, the literature evidence was rated as "HIGH" initially if the majority of the articles are levels I or II. It is rated as "LOW" if the majority were level III or lower. This is the "baseline" strength of evidence, online supplementary "4a: Critical Appraisal for Articles on Therapy." The consistency, directness, precision, and subgroup effects are considered for potential "downgrading" the strength of the body of evidence (one or two levels depending on the degree and number of domain violations).
Criteria Evaluated for "Downgrading"
• Consistency refers to the degree of similarity in the effect sizes of different studies within an evidence base. If effect sizes indicate the same direction of effect and if the range of effect sizes is narrow, an evidence base was judged to be consistent. If meta-analyses were conducted, we evaluated the consistency with an "eye ball test." This test consists of a visual appraisal of the forest plots by two independent reviewers. Single study evidence bases were judged "consistency unknown (single study)" and downgraded.
• Directness is concerned with whether the evidence being assessed reflected a single, direct link between the interventions of interest and the ultimate health outcome; that is, a determination of whether the most clinically relevant outcome was measured or if a surrogate outcome was assessed. Directness also applies to indirect comparisons of treatment when head-to-head comparisons of interest could not made within individual studies.
• Precision of evidence pertains to the degree of certainty surrounding an estimate of effect for a specific outcome. This is based on whether the estimate of effect reached statistical significance and/or the inspection of confidence intervals around effect estimates. When there are only two subgroups, the overlap of the confidence intervals of the summary estimates of the two groups is considered. No overlap of the confidence intervals indicates statistical significance, but the confidence intervals can overlap to a small degree and the difference still is statistically significant.
• Subgroup effects. For evaluating subgroup effects (i.e., heterogeneity of treatment effects), we downgrade if the authors do not state a priori their plan to perform subgroup analyses and if there was no test for interaction.
Criteria Used for "Upgrading"
• Finally, if the strength of evidence is less than "HIGH," we "upgrade" the evidence if there is a dose-response association or a strong magnitude of effect.
The following four possible levels and their definition are reported:
• High: High confidence that the evidence reflects the true effect. Further research is very unlikely to change our confidence in the estimate of effect.
• Moderate: Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of effect and may change the estimate.
• Low: Low confidence that the evidence reflects the true effect. Further research is likely to change the confidence in the estimate of effect and likely to change the estimate.
• Insufficient: Evidence either is unavailable or does not permit a conclusion. • XLIF from L1-L2 to L4-5 and MIS TLIF/transsacral fusion at L5-S1
• n ¼ 109 LOS • Implant fracture, replaced during surgery (n ¼ 1)
• Compression fracture, 4 wk post-op
• Deep wound infections (n ¼ 0)
Mortality
• Overall: 2.5% (1/40) (p < 0.0018 vs.
PLIF)
• 3 mo: (n ¼ 0)
• 6 mo: myocardial infarction (n ¼ 1)
• Open PLIF (historical cohort)
• n ¼ 20
Reoperation risk • Deep wound infections (n
• 6 mo: (n ¼ 1)
• 12 mo: (n ¼ 1)
Evidence-Based Spine-Care Journal Vol. • Injured ipsilateral L4 nerve root, residual motor effects at 1 year (n ¼ 2)
• Irritation of LFCN resulting in meralgia paresthetica, significant paresthesia at 1 year (n ¼ 6)
• Significant psoas muscle spasm (n
• Implant bone interface failure (n ¼ 1)
• Psoas muscle spasm on surgical side (n ¼ 5)
• Vascular: 0%
• Retrograde ejaculation: 0%
• Mortality: 0% (0/58)
• n ¼ 40 Poor quality cohort Good quality case-control or cross-sectional study
• Prospective design with violation of 2 or more criteria for good quality cohort, or • Retrospective design with violation of 1 or more criteria for good quality cohort • A good case-control study • A good cross-sectional study
IV
High risk Study has significant potential for bias; does not include design features geared toward minimizing bias and/or does not have a comparison group Poor quality case-control or cross-sectional Case series
• Other than a good case-control study • Other than a good cross-sectional study • Any case series design
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